Head & Neck Cancers

A group of researchers at Washington University in St. Louis recently opened a clinical trial to evaluate pembrolizumab as treatment intensification therapy for patients with high-risk locoregionally advanced, previously untreated, HPV-negative head and neck squamous cell carcinomas.

Olanzapine (Zyprexa) demonstrated an improvement in antinausea effects in patients receiving concurrent highly emetogenic chemotherapy and radiation therapy for advanced stage head and neck and esophageal cancer when compared to fosaprepitant.

Tanguy Seiwert, MD, assistant professor of medicine and associate leader of the head and neck cancer program, University of Chicago, discusses the efficacy of pembrolizumab in head and neck cancer.

Loren Scott Michel, MD, Assistant Professor Medicine, Washington University, medical oncologist Siteman Cancer Center, discusses the link between human papillomavirus (HPV) and oropharyngeal cancers.

Rindopepimut (Rintega) has gained a Breakthrough Therapy Designation from the FDA to treat adult patients with glioblastoma multiforme that test positive for the epidermal growth factor receptor variant.